Morgan Stanley
ZVSA

Morgan Stanley’s ZyVersa Therapeutics ZVSA Stock Holding History

Morgan Stanley’s Portfolio ZVSA Stock Details ZVSA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-1
Closed -$1 – 8291
2025
Q1 		$1 Hold
1
– – ﹤0.01% 8083
2024
Q4 		$1 Hold
1
– – ﹤0.01% 7963
2024
Q3 		$2 Buy
+1
New +$3 ﹤0.01% 7913

Other funds holding ZVSA

UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Morgan Stanley's ZVSA Position: Q2 2025 in Review

Morgan Stanley sold out of ZyVersa Therapeutics (ZVSA) in Q2 2025, closing a stake of 1 share — an estimated $1 sold.

Morgan Stanley first reported a position in ZVSA in Q3 2024 and held it in 3 quarters. The position peaked at $2 in Q3 2024. 6 funds tracked by Wall St. Rank hold ZVSA as of Q2 2025.

  • Morgan Stanley reported no remaining ZyVersa Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Morgan Stanley sold 1 ZyVersa Therapeutics share in Q2 2025, an estimated $1.
  • Morgan Stanley first reported a position in ZyVersa Therapeutics in Q3 2024 and held it in 3 quarters.
  • Morgan Stanley's ZyVersa Therapeutics position peaked at $2 in Q3 2024.
  • 6 funds tracked by Wall St. Rank held ZyVersa Therapeutics as of Q2 2025.

Based on Morgan Stanley's 13F filing for Q2 2025, filed 15 Aug 2025.